Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: J Immunol. 2019 Nov 6;203(12):3407–3415. doi: 10.4049/jimmunol.1900364

Figure 6.

Figure 6.

In vivo biomarker and metabolic effects of NX-13 in Mdr1a−/− mice. Mdr1a−/− mice were administered oral NX-13 (0, 10, or 20 mg/kg) daily for six weeks. Protein levels (A) of cytokines and chemokines in colon after six weeks were measured by Luminex; single asterisks mark significance relative to vehicle in the 20 mg/kg group and double asterisks mark significance at both 10 and 20 mg/kg. Expression of mt-Nd3 (B), mt-Co3 (C), Odgh (D), Eno1 (E), Gpx1 (F), and Gstm1 (G) were measured by qRT-PCR. Glutathione peroxidase (H) and glutathione (I) were measured in colon after six weeks of treatment. Data presented as mean ± SEM (n = 8). Asterisks mark significance (p ≤ 0.05).